We offer a Complete Range of Diagnostic and Treatment Services.
Expert care is available for patients experiencing any degree of IBD, from mild cases requiring only minor medication changes and lifestyle adaptations, to extreme cases demanding technically sophisticated intervention.
Each patient is evaluated and a personalized treatment plan is developed. Review of previous endoscopies, radiologic studies, and pathology is provided by gastroenterologists whose sole focus is IBD.
Because effective management of an IBD patient hinges on pinpointing the exact type, extent, and severity of the disease, our Center offers a range of highly sophisticated diagnostic options, including wireless capsule endoscopy pioneered by Mount Sinai gastroenterologists. Novel radiologic imaging approaches such as CT enterography and MR enterography are also available, allowing examination of complications in exceptional anatomic detail.
When non-invasive testing is inconclusive, laparoscopy performed by world leaders in this technique can be used safely to diagnose the most difficult cases.
At Mount Sinai’s Center for Inflammatory Bowel Disease, patients benefit from individualized treatment plans that combine the latest medical or surgical therapies with established approaches.
Our inpatient service is expert at caring for patients requiring intravenous cyclosporine therapy. At our infusion center, specially-developed protocols permit the safe administration of infliximab (Remicade), even to patients with prior infusion reactions. Other infusion-based therapies such as human intravenous gammaglobulin, leukocytapharesis, and intravenous iron are also administered.
Bowel-sparing surgery has been performed at Mount Sinai on thousands of patients with Crohn’s disease. For patients with ulcerative colitis failing medical therapy or with dysplasia, restorative proctocolectomies can be performed in one or two stages by highly experienced surgeons, frequently using minimally invasive approaches. Our colorectal surgeons can also provide relief for patients with perianal complications of Crohn’s disease.
For patients who have endured the unfortunate consequences of extensive surgery for Crohn's disease, Mount Sinai's Intestinal Failure and Transplantation Program offers intestinal rehabilitation and transplantation.
Cutting Edge Research: Clinical Trials
Clinical trials conducted at Mount Sinai have changed the face of therapy for inflammatory bowel disease. These include 6-mercaptopurine, cyclosporine, and, most recently, infliximab and anti-interleukin-12 antibody for active Crohn’s disease. Consistent with the program’s strong research focus on the genetic, immunologic, and microbiologic aspects of IBD, Mount Sinai regularly conducts clinical trials in the areas of biologic therapy, leukocytapharesis and other types of immunomodulatory therapy for patients with severe or treatment-resistant forms of IBD.
For a current list of Clinical Trials now open to patients at Mount Sinai, please click here.
Basic Science Research
Many of the clinicians caring for patients at the Center for Inflammatory Bowel Disease are at the forefront of immunologic research that will ultimately lead to improved IBD therapies. Our unique bench-to-bedside approach gives patients early access to the fruits of their discoveries.
In particular, the research at Mount Sinai focuses on the immunologic response to bacteria in the gut, the development of tolerance to luminal antigens, the molecular pathways leading to cancer development in IBD, and the genetics of the disease. Our research is supported by the National Institutes of Health and the Crohn’s and Colitis Foundation of America.
Tel: 212-241-4299 (IBD Physician Referral Hotline)
The Center for Inflammatory Bowel Disease
The Mount Sinai Hospital
1425 Madison Avenue
New York, NY 10029
Out of nearly 5,000 hospitals evaluated, Mount Sinai ranks #9 in the nation for Digestive Disease in the 2013-2014 "Best Hospitals" issue of U.S. News & World Report. Learn More